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Novelty statement: The outlined paper analyzes 392 diabetes centers with 31119 patients 
with autoimmune diabetes for the prevalence and comorbidities of double diabetes. We could 
show for the first time that insulin requirement or insulin resistance is an independent risk 
factor for patients with type 1 diabetes and that even in well controlled diabetes an additional 
metabolic syndrome is a major risk factor for developing macrovascular as well as 
microvascular complications. 
 
Abbreviations: BMI: body mass index; DCCT: Diabetes Control and Complications Trial; 
DD: double diabetes; DPV: Diabetes-Verlaufs-Dokumentation; EDC: Epidemiology of 
Diabetes Complications study; GAD-AB: glutamatdecarboxylase antibodies; HDL: high 
density lipoprotein; LDL: low density lipoprotein; MS: metabolic syndrome; NCEP: National 
Cholesterol Education Program; PAD: peripheral arterial disease; T1DM: diabetes mellitus 
type 1; T2DM: diabetes mellitus type 2; UKPDS: United Kingdom Prospective Diabetes 
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Abstract 
Background: A growing number of people with type 1 diabetes (T1DM) are identified with 
features of metabolic syndrome (MS) known as “double diabetes”, but epidemiologic data on the 
prevalence of MS in T1DM and its comorbidities are still lacking.  
Aim of this cross sectional study is to better estimate the prevalence of MS in T1DM, and to 
assess its association with comorbidities. 
Methods: Data of 31119 persons with autoimmune diabetes mellitus were analyzed for signs of 
MS and presence of late complications. Double diabetes was defined as T1DM coexisting with 
MS (obesity, hypertension, dyslipidemia). Multiple linear or logistic regression analyses were 
performed to identify associations between double diabetes and late complications. 
Results: 25.5% (n=7926) of persons with T1DM presented additionally the MS. Persons with 
double diabetes showed significantly more macrovascular comorbidities (coronary heart disease 
8.0 versus 3.0% w/o MS, stroke 3.6 versus 1.6%, diabetic foot syndrome 5.5% versus 2.1%). 
Also microvascular diseases were increased in people with double diabetes (retinopathy 32.4% 
versus 21.7%, nephropathy 28.3% versus 17.8%). Both macrovascular and microvascular 
comorbidities were increased independent of glucose control, even if patients with good 
metabolic control (HbA1c <7.0%, 53mmol/mol) showed significantly less macrovascular 
(coronary heart disease 2.3% versus 1.8%, p<0.0001) and microvascular problems (retinopathy 
8.7% versus 6.6%, p<0.0001). 
Conclusions: Double diabetes seems to be an independent and important risk factor for persons 
with T1DM in developing macrovascular and microvascular comorbidities. Therefore, patients 
should be identified and development of MS should be avoided. Longtermstudies are needed to 
observe the effect of insulin resistance on patients with autoimmune diabetes. 
 
 
1. Introduction: 
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Autoimmune diabetes mellitus (Type-1DM) with an autoimmune loss of insulin producing beta 
cells has for quite a long time been clearly separated from MS and diabetes mellitus type 2, 
where insulin resistance and a relative insulin deficiency is the more relevant pathophysiology 
[1]. During the last years increasing evidence demonstrated, that the clinical phenotype of people 
with T1DM presents with a broad range of clinical features and that increasing numbers of 
patients show signs of MS as abdominal obesity, arterial hypertension, dyslipidaemia, , up to 
now not considered a clinical feature of diabetes mellitus type 1 [2, 3]. These persons often have 
a family history of type 2 diabetes (T2DM) [4] or hypertension [5]. Genetic similarities are seen 
between obese people with autoimmune diabetes and T2DM [6]. The prevalence of persons 
showing signs of both diabetes forms increases significantly because of lifestyle changes in the 
last decades with increasing obesity and decreasing physical activity, but epidemiologic data 
about this phenomenon are still scarce [2, 7, 8]. Recently, the combined presentation of features 
of both type 1 and type 2 diabetes has been referred to as “double diabetes”, e.g. when a person 
with T1DM becomes overweight/obese and insulin resistance increases [3, 7, 9].  
Aim of the following study is to analyse the prevalence of MS - defined according to the NCEP 
(National Cholesterol Education Program) criteria as obesity, dyslipidaemia and arterial 
hypertension combined with insulin resistance - in people with T1DM [10].  
 
2. Materials and Methods: 
2.1.Patients and data documentation 
Patients were selected from the DPV [Diabetes-Verlaufs-Dokumentation] registry, a computer-
based documentation program for all diabetes-related aspects of diagnosis and patient care. The 
database includes patients with all types of diabetes and is currently used by 392 specialized 
centres of the DPV Initiative from Germany and Austria. Prospectively documented data, after 
anonymisation, are transmitted twice a year from participating health care facilities to the central 
database in Ulm, Germany, for quality assurance and statistical analysis [11, 12]. Implausible 
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and inconsistent data are reported back to the centres of origin for verification and correction. 
The DPV Initiative, and analyses based on anonymised data in the DPV database, are approved 
by the Ethics Committee of the University of Ulm, Germany. 
For the present analysis, data from patients aged  18 years with a clinical diagnosis of insulin 
dependent T1DM were selected. Diabetes mellitus type 1 was defined as initially insulin 
dependent diabetes mellitus with at least one diabetes specific antibody. Data transmitted prior to 
September 2013 were included into this analysis. Up to this time-point, 40046 patients  18 
years were registered in DPV, 32871 showed all necessary data including BMI and insulin dose, 
patients who had a co-medication of sulfonylurea or who had no documented diabetes-specific 
antibodies were excluded (n=1752, leaving  n=31119 participants in the analysis). Information 
about gender, age, and diabetes duration was available for all subjects. For analysis of glycaemic 
control, individual mean HbA1c was standardized to the Diabetes Control and Complications 
Trial (DCCT) normal range by the ‘‘multiple of the mean method’’ [13] based on the local 
HbA1c reference ranges, HbA1c was measured bei immunological tests, LDL by 
ultracentrifugation.  
Diabetes associated kidney diseases were classified according to the German National Diabetes 
Guideline [14] into microalbuminuria (albumin excretion in morning urine 20-200 mg/l) and 
macroalbuminuria (>200 mg/l). Dyslipidemia and arterial hypertension are defined according to 
the NCEP criteria [10]. 
MS was defined according to the NCEP criteria, if participants show at least three criteria out of 
obesity (waist circumference > 40 inches in male, >35inches in female or BMI>30kg/m2), 
hyperglycaemia present in all participants since all are diagnosed with diabetes mellitus, 
dyslipidaemia or arterial hypertension [10]. Of all 31119 documented people with T1DM, 7926 
fulfilled the criteria of the MS (double diabetes, DD), the rest (n=23193) were considered type 1 
diabetic persons without MS (T1DM w/o MS). To discriminate effects of blood glucose control 
from those of MS a subgroup analysis for people with well controlled diabetes as defined by 
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HbA1c <7% (53mmol/mol) was performed (n= 9203, double diabetes n= 1892, no double 
diabetes n=7311) (Fig.1).  
2.2. Statistical analysis 
For categorical variables, proportions were used for description. As not all continuous 
parameters were normally distributed based on QQ plots, descriptive statistics with mean values 
and standard error were calculated for continuous variables. For unadjusted group comparisons, 
Kruskal-Wallis-test for continuous variables and 2-test for binary variables were used. 
Bonferroni-stepdown adjustment was used to correct p-values for multiple testing.  
To consider possible confounding effects as sex, age or diabetes duration on the comparison 
between type-1-patients and double-diabetes-patients, linear regression models were created with 
treatment centre as random effect. Iterations were optimized according to Newton-Raphson, and 
denominator degrees of freedom were calculated by the between-within-method (SAS, proc 
glimmix). For binary variables, multivariable logistic regression models were created. Adjusted 
means/percentages (LS-Means) were calculated for 40-year-old patients with a diabetes duration 
of 15 years, assuming equal numbers of men and women. Regression models were implemented 
for all patients, as well as separately for patients with good metabolic control defined by HbA1c 
< 7 %, 53mmol/mol.   
All statistical analyses were implemented with SAS 9.4 (Statistical Analysis Software, SAS 
Institute, Cary, NC, USA).  A two-sided p-value <0.05 was considered statistically significant. 
 
3. Results 
3.1. Study population 
In the DPV database, 31119 adult people (>18 years) with diabetes mellitus type 1 were 
identified (table 1). 7926 (25.4%) met the definition of MS (double diabetes) [10]. Baseline 
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characteristics of patients with and without metabolic syndrome are presented in Table 1 and 
Table 2.  
People with double diabetes had developed diabetes at a higher age (24.9 years, IQR 25.6 versus 
15.8 years, IQR 19.7) and showed a higher percentage of males (Table 1). Mean age in the 
double diabetes group (DD) was 44.7 years ± 18.6 versus 36.2 years ± 18.3. Diabetes duration 
was longer in people with T1DM with MS (Table 1). Metabolic control as measured by HbA1c 
was worse in persons with double diabetes (mean HbA1c 8.5(69mmol/mol) ± 0.051% versus 
8.0±0.048%, p < 0.0001), when adjusted for age, sex and diabetes duration.  
Persons with double diabetes required a significantly higher daily insulin dose (Table 2), as well 
as a higher dose per kg body weight. This effect was even more significant when adjusted for 
age, sex, and diabetes duration. In well controlled diabetes (HbA1c < 7% (53mmol/mol), p 
<0.0001) daily insulin requirement did show a similar difference but persons had a lower insulin 
need per kg bodyweight when adjusted for age, sex and diabetes duration (Table 2) compared to 
the entire group. Dyslipidaemia was also seen in people with T1DM without MS (84.1% in DD 
versus 53.9%, Table 2). After adjustment for demographic differences cholesterol levels were 
higher in double diabetes, HDL was lower, LDL was higher, even if a higher percentage of 
people with double diabetes were taking lipid lowering medication (27.8% versus 10.3%). 
Arterial hypertension was still more frequent in coexisting MS, even if more people with double 
diabetes were on antihypertensive medication (47.2 versus 18.4%) (Table1). Smoking habits 
were not significantly different in both groups (28.5% versus 27.3%, p= 0.2283) but smoking 
was significantly more present in DD patients once adjusted for age, sex and diabetes duration 
(Table 2). People with well controlled diabetes had a lower proportion of smokers, both in the 
DD and the only T1DM groups (Table 2). 
Persons with double diabetes did not show significant differences in beta cell antibody 
distribution compared to people with T1DM without MS: GAD-AB (glutamatdecarboxylase 
antibodies) 87.8 versus 86.1%, p=0.986, IA2 antibodies 68.4 versus 69.2%, p=0.842, (Table 2). 
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Additional autoimmune diseases were seen in both groups as well: about one quarter had thyroid 
antibodies (Table 2). Antibodies to tissue transglutaminase are seen in 16.9% of the people with 
double diabetes and 15.3% of persons without MS (p=0.18), but clinical diagnosis of coeliac 
disease differs only in people with HbA1c < 7% (53mmol/mol) (Table 2).   
 
3.2. Macrovascular diseases 
People with T1DM and MS showed a significantly higher prevalence of macrovascular diseases 
(Fig. 2), especially of ischemic heart disease (8% versus 3%, p< 0.0001). This effect is seen in 
all patients (Fig. 2). In well controlled diabetes the difference between persons with and without 
MS is less pronounced (2.7% versus 1.3%). However adjusted for age, gender and diabetes 
duration this effect remains highly significant (2.6%versus 1.4%, p< 0.0001). The lowest risk is 
seen in well controlled T1DM without MS (Fig.2). The macrovascular problems take place even 
if the patients with MS had significantly more antihypertensive (47.2% versus 18.8%) and lipid 
lowering drugs (24.5% versus 9.1%). Myocardial insufficiency is defined according to the 
National Guidelines as reduced pump function [15]. 
A history of stroke was twice as common in people with double diabetes compared to T1DM 
without MS (Fig. 2). Adjusted for age, gender and diabetes duration, the difference is highly 
significant (1.39% versus 0.87%, p<0.0001). The same effect is seen in adjusted data for diabetic 
foot syndrome [16, 17] (1.3 versus 0.76, p<0.0001) and PAD (0.4% versus 0.24%, p<0.0001). In 
people with good blood glucose control, PAD and diabetic foot syndrome were reduced to less 
than half (Fig.2, p<0.0001), but again two times as frequent in persons with double diabetes 
(p<0.0001, Fig. 2).  
 
3.3. Microvascular diseases 
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The same pattern is seen in microvascular complications: persons with double diabetes show an 
increased risk for retinopathy and nephropathy (Fig. 3). Adjusted for age, gender and diabetes 
duration, 16.2% of subjects with double diabetes showed diabetic retinopathy versus 12.4% of 
T1DM without MS (p<0.0001). For proliferative retinopathy the frequencies were 8.0% versus 
5.4% (p<0.0001). Subgroup analysis in people with HbA1c<7% (53mmol/mol) showed a lower 
prevalence of diabetic retinopathy in both groups (8.7% with versus 6.6% without MS, 
p<0.0001), but compared to the macrovascular comorbidities, risk reduction was less dependent 
on MS than on good metabolic control. Nephropathy is also seen more often in T1DM with MS 
(Fig. 3). Adjusted for demographic factors, 22.6% of the people with double diabetes showed 
microalbuminuria (3.6% a macroalbuminuria) compared to 16.03% (1.96%) of the T1DM 
without MS (both p<0.0001). The well controlled subgroup with MS displayed 6.8% 
micoalbuminuria compared to 5.0%, in people without MS (p<0.0001). For macroalbuminuria 
the frequencies were 1.4% versus 0.9% (p <0.0001). Taking together, double diabetes is an 
independent risk factor for all microvascular comorbidities even if good metabolic control seems 
to show a bigger impact (Fig.3). 
 
4. Discussion 
The phenotype of T1DM mellitus changed in the last decades [3]. Life style changes with a lack 
of physical activity and high caloric food as well as better medical care with intensified insulin 
therapies in persons with insulin dependent diabetes result in an increasing number of obese 
subjects with T1DM. In this cross sectional analysis of a cohort of 31119 people with T1DM 
mellitus, 30.9% (n=9616) were overweight, 13.5% obese (Table 2). Compared to DCCT (BMI 
23.5±2.9 kg/m2 [18]), or the diabetomobile study (BMI 24,2 kg/m2 [19]), BMI of our study 
cohort was 25.27± 6.09 kg/m2  (Table 2), so average BMI increased remarkably in people with 
type1 diabetes over the last 20 years. One possible reason is the change in therapy of T1DM over 
the last decades: Whereas early patients with T1DM were trained to a strict diet and a non-
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flexible insulin regimen to avoid diabetes complications, multiple daily insulin injection regimen 
according to the basis bolus principle allow for more flexible mealtimes and more frequent 
snacks, which could contribute to weight gain [13]. Eating behaviour also changed during the 
last decades with more fast food eaten also by people with diabetes mellitus type 1. Especially 
dietary fat seems to have a major impact on insulin resistance and body weight [20]. But obesity 
is not the only risk factor in people with T1DM: 57.6% (n=17471) of all T1DM analysed showed 
either elevated blood pressure or took antihypertensive drugs, 61.6% (n=19167) showed 
dyslipidaemia (Table 2). So using the NCEP criteria [10], 25.5% (n=7926) of the study cohort 
showed the MS together with T1DM (Table 2). In people with well controlled T1DM mellitus, 
20.6% (n=1892) showed double diabetes. In people with MS the quality of blood sugar control 
was significantly worse than in T1DM without MS (Table 1, 2). But only 51.3% of our analysed 
people with autoimmune diabetes had a normal body mass index (Table 1) which is only slightly 
better than the average non diabetic German population where only 48% have a normal body 
mass index [21]. Therefore increasing interest should be directed to the field of double diabetes, 
defined as T1DM mellitus with criteria of the MS [2, 7, 8, 22]. Since patients with MS show an 
augmented cardiovascular risk, increasing effort should be taken to identify persons with T1DM 
and MS to reduce their mortality.  
Kilpatrick et al. showed in a cohort of 1337 patients that estimated glucose disposal rate as a 
marker of insulin resistance is linked to a higher risk of cardiovascular diseases [2]. So these 
patients showed a higher insulin need than non double-diabetes patients. Our data verify this 
effect in 31119 persons (table 2). In our study, double diabetic persons needed significantly more 
daily insulin in total as well as per kg bodyweight. This is especially interesting, because 
previous studies could not see a significant difference in the daily amount of insulin, probably 
due to the small number of persons analysed [2]. So the daily need of insulin seems to be an easy 
marker to estimate insulin resistance in insulin dependent diabetes persons. Subjects with good 
blood glucose control had a tendency to need less insulin. One possible explanation might be that 
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people with better metabolic control show more interest in their health and do more sports, 
which lowers the insulin need and the body weight. Clinical experience also underlines that 
insulin requirement depends on blood sugar control even if clinical trials addressing this topic 
are rare [23]. Also these patients more often show different eating behaviours and possibly 
consume fewer calories. Another possibility could be reduced stress in patients with good blood 
glucose control and therefore lower stress hormone levels which decreases insulin resistance [24, 
25]. Insulin regimen thereby did not show any relevant differences, besides that the obese 
persons use slightly more often insulin pumps (CSII) and slightly less often conventional insulin 
therapy whereas no significant difference in intensified conventional therapy was seen (Table 1). 
The autoimmune characteristics did not show significant differences between double diabetes 
and T1DM without MS (Table 1, 2) but people with double diabetes develop diabetes at a higher 
age, so probably genetic differences also contribute to the risk of double diabetes [26]. So since 
the genetic burden of the metabolic syndrome is quite high, it might also be possible, that people 
with DD inherit the T2DM genes from their parents on top of the T1DM, here genetic 
analysation should be carried out in people with DD. 
 
People with double diabetes show a significant increase in all macrovascular comorbidities, 
especially in myocardial infarction (Fig. 2) [27]. Although it is well established that good 
metabolic control reduces the risk of macro- and microvascular endpoints and mortality [28, 29], 
MS is an independent risk factor for the development of comorbidities: The participants with 
double diabetes and HbA1c below 7% (53mmol/mol) had a significantly higher prevalence of 
macrovascular complications than well controlled persons with T1DM without MS 7% (Fig. 2). 
This highlights that MS is an independent cardiovascular risk factor in patients with T1DM. 
Insulin resistance is known to have a major impact on the cardiovascular outcome of patients 
with T2DM [30], but is seems to be a major risk factor in patients with T1DM as well (Fig. 2) 
[2]. Especially in peripheral arterial disease and diabetic foot syndrome, patients showed nearly 
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the same risk comparing well controlled double diabetes and not well controlled diabetes type 1 
without MS (Fig. 2). These data suggest that double diabetes entails a higher risk for any type of 
macrovascular comorbidities resulting in a higher prevalence of such events compared to data of 
UKPDS, EDC, EDIC or EURODIAB [28, 31, 32]. Double diabetes subjects thereby show a risk 
for cardiovascular comorbidities similar to patients with T2DM. Efforts are required to address 
the clinical problem of obesity and MS in persons with T1DM in order to reduce the risk for late 
complications. The number of people with T1DM and MS who are treated additionally with 
insulin resistance lowering substances as Metformin or weight reducing substances as GLP-
1(glucagon like peptide 1)-analogues are still too small to see a possible effect. Here clinical 
trials should evaluate the output of different methods of weight and insulin resistance reduction 
in people with T1DM.  
Microvascular comorbidities are known to be linked to blood sugar control [33], but patients 
with T2DM are known to have a higher risk of diabetic nephropathy than people with T1DM 
[34]. In our study, subjects with double diabetes show a significantly higher prevalence of 
diabetic nephropathy than T1DM without MS (Fig. 3) [2], which was comparable to that seen in 
T2DM [33].  
Diabetic retinopathy was also more prevalent in persons with double diabetes (Fig. 3) [2]. People 
with good metabolic control had a lower prevalence of non proliferative retinopathy in both the 
obese and non-obese groups. Here the risk in developing eye complications was more dependent 
on blood sugar control than on insulin resistance. However, the presence of MS in the subgroup 
of persons with well controlled diabetes increased risk significantly.   
 
4.1. Limitations of the study 
A minimal selection bias might not be totally excluded in the group of uncomplicated diabetes 
type1, since some of them have been treated only by their family doctor and different centers 
might use heterogeneous documentations. 
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The macrovascular events are evaluated retrospectively and not prospectively, which might also 
cause differences. 
HbA1c levels were not measured centrally. In order to reduce inter laboratory variations of 
HbA1c values, they were standardized according to DCCT, using the multiple of the mean 
method. 
 
4.2. Conclusion 
Taking together, MS in T1DM is associated with increased prevalence of macro- and 
microvascular complications, even in those with good glycaemic control. Lifestyle modifications 
as physical exercise, healthy diet and weight reduction have to be acknowledged as essential 
therapeutic strategies, not only for type 2 but also for T1DM persons, in order to improve quality 
of life and survival. People with double diabetes are a special risk population, because the 
awareness for their metabolic comorbidities is lacking and stronger efforts are necessary to 
identify these patients and explore strategies to reduce the rate of MS in T1DM. 
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Figures: 
Figure 1: Selection of study population from the DPV database, MS was defined according to 
the NCEP criteria, if participants show at least three criteria out of obesity (waist circumference 
> 40 inches in male, >35inches in female or BMI>30kg/m2), hyperglycaemia which all 
participants show since all are diagnosed with diabetes mellitus, dyslipidaemia or arterial 
hypertension. 
Table 1: Baseline characteristics of all persons from DPV database, for T1DM people with 
(double diabetes) or without MS (T1DM w/o MS) as defined by NCEP criteria.  
Table 2: Baseline clinical characteristics of persons from DPV database, for T1DM people with 
(double diabetes) or without MS (T1DM w/o MS) as defined by NCEP criteria. Data were 
adjusted for sex, age and diabetes as mentioned in Material and Methods. 
Figure 2: prevalence of macrovascular diseases in people with T1DM mellitus, the data present 
the percentage of persons in relation to all persons with double diabetes (n=7926) or in relation 
to people with T1DM without MS (T1DM w/o MS, n= 23193). Double diabetes all: all people 
with type1 diabetes and MS; double diabetes, HbA1c<7% (53mmol/mol): persons with double 
diabetes with good blood glucose control (n=1892); T1DM w/o MS all: all persons with T1DM 
who did not meet the NCEP criteria of the MS (n=23193); T1DM w/o MS HbA1c<7% 
(53mmol/mol): persons with T1DM and good glucose control who did not meet the NCEP 
criteria of the MS (n=7311). Data were adjusted for sex, age and diabetes as mentioned in 
Material and Methods 
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Figure 3:  prevalence of microvascular diseases in people with T1DM mellitus, the data present 
the percentage of persons in relation all persons with double diabetes or in relation to people 
with T1DM without MS (T1DM w/o MS). Double diabetes all: all people with type1 diabetes 
and MS(n=6502); double diabetes, HbA1c<7% (53mmol/mol): persons with double diabetes 
with good blood glucose control (n=1512); T1DM w/o MS all: all persons with T1DM who did 
not meet the NCEP criteria of the MS (n=16721); T1DM w/o MS HbA1c<7% (53mmol/mol): 
persons with T1DM who did not meet the NCEP criteria of the MS but show HbA1c <7% 
(53mmol/mol) (n=5072). Data were adjusted for sex, age and diabetes as mentioned in Material 
and Methods 
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Figure 1: Selection of study population from the DPV database, MS was defined according to 
the NCEP criteria, if participants show at least three criteria out of obesity (waist circumference 
> 40 inches in male, >35inches in female or BMI>30kg/m2), hyperglycaemia which all 
participants show since all are diagnosed with diabetes mellitus, dyslipidaemia or arterial 
hypertension. 
Table 1: Baseline characteristics of all persons from DPV database, for T1DM people with 
(double diabetes) or without MS (T1DM w/o MS) as defined by NCEP criteria.  
Table 2: Baseline clinical characteristics of persons from DPV database, for T1DM people with 
(double diabetes) or without MS (T1DM w/o MS) as defined by NCEP criteria. Data were 
adjusted for sex, age and diabetes as mentioned in Material and Methods. 
Figure 2: prevalence of macrovascular diseases in people with T1DM mellitus, the data present 
the percentage of persons in relation to all persons with double diabetes (n=7926) or in relation 
to people with T1DM without MS (T1DM w/o MS, n= 23193). Double diabetes all: all people 
with type1 diabetes and MS; double diabetes, HbA1c<7% (53mmol/mol): persons with double 
diabetes with good blood glucose control (n=1892); T1DM w/o MS all: all persons with T1DM 
who did not meet the NCEP criteria of the MS (n=23193); T1DM w/o MS HbA1c<7% 
(53mmol/mol): persons with T1DM and good glucose control who did not meet the NCEP 
criteria of the MS (n=7311). Data were adjusted for sex, age and diabetes as mentioned in 
Material and Methods 
Figure 3:  prevalence of microvascular diseases in people with T1DM mellitus, the data present 
the percentage of persons in relation all persons with double diabetes or in relation to people 
with T1DM without MS (T1DM w/o MS). Double diabetes all: all people with type1 diabetes 
and MS(n=6502); double diabetes, HbA1c<7% (53mmol/mol): persons with double diabetes 
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with good blood glucose control (n=1512); T1DM w/o MS all: all persons with T1DM who did 
not meet the NCEP criteria of the MS (n=16721); T1DM w/o MS HbA1c<7% (53mmol/mol): 
persons with T1DM who did not meet the NCEP criteria of the MS but show HbA1c <7% 
(53mmol/mol) (n=5072). Data were adjusted for sex, age and diabetes as mentioned in Material 
and Methods 
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Table 1:  
  double 
diabetes 
  T1DM 
w/o MS 
  p-value  p-value  
  all HbA1c<7% 
(53mmol/m
ol) 
all HbA1c<7% 
(53mmol/m
ol) 
all HbA1c<7% 
(53mmol/m
ol) 
numbers 7926 1892 23193 7311 n.a n.a 
male (%) 54.3 55.7 53.1 54.2 n.a n.a 
female (%) 44.7 44.3 44.8 45.8 n.a n.a 
age (y) 44.7 ± 
18.6 
50.6 ± 17.8 36.2 ± 
18.3 
40.2 ± 18.9 <0.0001 <0.0001 
diabetes 
duration (y) 
17.6 ± 
14.1 
21.2 ±14.9 15.0 ± 
12.7 
17.1 ± 14.0 <0.0001 <0.0001 
age at diagnosis 
(y) 
27.1 ± 
16.8 
29.3 ± 16.8 21.2 ± 
15.3 
23.1 ± 15.3 <0.0001 <0.0001 
insulin regime             
ICT 64.0 62.7 61.9 60.7 0.0013 0.9021 
CSII 21.2 20.5 23.6 22.3 <0.0001 0.8023 
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Table 2: 
  double 
diabetes 
  T1DM 
w/o MS 
  p-value  p-value  
  all HbA1c<7% 
(53mmol/mo
l) 
all HbA1c<7% 
(53mmol/mo
l) 
all HbA1c<7% 
(53mmol/mo
l) 
BMI (kg/m2) 28.9  ± 7.1 29.7 ± 5.7 24.0 ± 
5.1 
24.3 ± 6.8 <0.000
1 
<0.0001 
BMI < 
19kg/m2 (%) 
2.0 1.4 4.7 3.7 n.a n.a 
BMI 19-
24.99kg/m2 
(%) 
26.7 20.3 60.1 59.1 n.a n.a 
BMI 25-
29.99kg/m2 
(%) 
26.9 27.1 32.2 34.2 n.a n.a 
BMI30-
34.99kg/m2(
%) 
31.5 37.1 2.3 2.3 n.a n.a 
BMI>35kg/m
2 (%) 
12.9 14.0 0.6 0.7 n.a n.a 
waist (cm) 98.9 ±  32.2 99.3  ± 12.2 84.9  ± 
10.3 
85.8  ±  10.5 <0.000
1 
<0.0001 
HbA1c (%) 
(mmol/mol) 
8.5 ± 0.051 
69 ± 0.7 
6.3±0.01 
45. ± 0.00 
8.0 ± 
0.048 
64.± 1.0 
6.3±0.01 
45± 0.00 
<0.000
1 
n.a 
insulin dose 
(I.U.) per day 
71.34 ± 0.64 65.97 ±0.81 56.09 ± 
0.59 
49.92±0.59 <0.000
1 
<0.0001 
insulin dose 
(I.U.) per kg 
BW 
0.865±0.008
7 
0.782±0.010 0.801 ± 
0.0080 
0.711±0.008 <0.000
1 
<0.0001 
Dyslipidemia 
(%) 
84.1 78.4 53.9 47.9 <0.000
1 
<0.0001 
LDL mg/dl 116.2 ±45.2 110.3 ± 44.7 103.8 
±36.6 
101.1 ± 35.6 <0.000
1 
<0.0001 
HDL (mg/dl) 49.4 ± 21.1 49.9 ±9 65.8 ± 
20.5 
67.7 ± 19.8 <0.000
1 
<0.0001 
triglycerides 
(mg/dl) 
206.1 ± 
162.5 
177,1 ± 
128.3 
100.7 ± 
68.1 
87.9 ± 14.2 <0.000
1 
<0.0001 
arterial 
Hypertension 
(%) 
40.5 44.1 23.3 24.0 <0.000
1 
<0.0001 
systolic BP 
(mmHg) 
134.4 ± 15.8 135.2 ± 15.8 125.6 ± 
15.0 
126.1 ± 15.4 <0.000
1 
<0.0001 
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diastolic BP 
(mmHg) 
78.4 ± 10.1 77.8 ± 10.3 74.4 ± 
9.8 
74.3 ± 10.3 <0.000
1 
<0.0001 
smoker (%) 23.0 17.9 21.4 16.0 0.0104 0.1143 
diabetes 
specific  
antibodies 
            
GAD (%) 87.8 89.7 84.9 85.2 0.7165 0.9948 
IA2 (%) 68.5 71.4 72.0 75.1 0.7100 0.9252 
ICA (%) 63.1 66.2 70.2 73.4 0.2511 0.6930 
Thyroid 
antibodies 
(%) 
24.9 26.2 25.6 24.9 0.5461 0.8059 
Clinical 
diagnosis of 
coeliac 
disease (%) 
0.7 0.4 1.2 1.2 0.1767 0.0470 
 
 
  
  
T1DM >18 y 
n = 40046 
BMI/insulindose documented 
n= 32871 
People  with T1DM with measured 
Diabetes specific antibodies and without 
sufonylurea comedication  
  n = 31119 
Double Diabetes 
n = 7926 
T1DM w/o MS 
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well controlled 
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a metabolic syndrome 
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